Want to see EDIT full AI Analyst Report?

Editas Medicine (EDIT) Price & Analysis

3,578 Followers

EDIT Stock Chart & Stats

$3.49

-$0.10(-7.24%)

At close: Jan 08 4:00 PM EST

$3.49

-$0.10(-7.24%)

Day’s Range― - ―

52-Week Range$1.66 - $4.54

Previous CloseN/A

Volume963.61K

Average Volume (3M)1.70M

Market Cap

$457.32M

Enterprise Value$190.09

Total Cash (Recent Filing)$123.65M

Total Debt (Recent Filing)$71.97M

Price to Earnings (P/E)―

Beta2.41

Next Earnings

Aug 05, 2026

EPS Estimate

-0.27

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.23

Shares Outstanding153,461,840

10 Day Avg. Volume1,781,207

30 Day Avg. Volume1,697,905

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)6.67

Price to Sales (P/S)4.49

P/FCF Ratio-1.10

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$7.20

Price Target Upside106.30% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

EPS Forecast (FY)-0.99

Revenue Forecast (FY)$14.33M

Bulls Say, Bears Say

Bulls Say

Promising EDIT-401 Preclinical EfficacyDurable, high-magnitude LDL and ApoB reductions in non-human primates and favorable pre-IND feedback materially de-risk EDIT-401 as a potential one-time gene-editing therapy. If translatable to humans, this confers a structurally differentiated product opportunity in hyperlipidemia and supports sustained clinical prioritization and long-term commercial optionality.

Extended Cash Runway From Equity RaiseA sizeable $125M offering meaningfully extends funding visibility into 2H 2028, reducing near-term liquidity pressure and enabling multiyear clinical development cadence. This structural extension improves the firm's ability to hit clinical milestones without immediate reliance on ad hoc financings, lowering execution risk over the medium term.

Board And Governance ContinuityShareholder approval of directors, executive compensation, and the auditor signals governance stability and investor confidence in leadership. Strong governance continuity supports consistent strategy execution, more effective oversight of complex clinical programs, and steadier decision-making across multi-year development milestones.

Bears Say

Severely Eroded Equity And Higher LeverageA collapse in equity and materially higher leverage materially reduce financial flexibility and the firm's ability to absorb setbacks. With a thin equity cushion, covenant constraints or rising interest costs could limit strategic options, forcing conservative program choices or near-term financing even if core programs perform as expected.

Persistent, High Cash BurnSustained negative operating and free cash flow requires repeated external funding or partner monetization to sustain R&D. High burn narrows runway assumptions, increases dilution risk over multiple financing cycles, and forces prioritization that can slow broader pipeline advancement if capital must be conserved.

Declining Revenue And Deep Operating LossesTop-line contraction and outsized negative margins highlight a structural mismatch between spending and current revenue scale. Until clinical programs progress to value-generating partnerships or commercialization, persistent losses threaten sustainability and require continual capital raises that can dilute long-term shareholder value.

Editas Medicine News

Editas Medicine Shareholders Back Board, Pay and Auditor

An announcement from Editas Medicine ( ($EDIT) ) is now available. At its June 17, 2026 annual meeting,...

1M ago

EDIT

Private Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO

Jeff Bezos’ new AI venture Prometheus has raised $12B in fresh funding, pushing its valuation to about $41B....

1M ago

Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI

After Editas Medicine (EDIT) presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an...

2M ago

EDIT

TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’

TD Cowen notes that Editas Medicine (EDIT) presented “compelling preclinical data” at EAS detailing EDIT-401’s 90% reduction in...

2M ago

EDIT

Editas Medicine Raises Capital Through Public Equity Offering

An announcement from Editas Medicine ( ($EDIT) ) is now available. On May 26, 2026, Editas Medicine, Inc....

2M ago

EDIT

Editas Medicine 55.6M share Secondary priced at $2.25

Cantor Fitzgerald and Wells Fargo acted as joint book running managers for the offering. Published first on TheFly...

2M ago

EDIT

Editas Medicine Suspends Existing At-The-Market Offering Prospectus

Editas Medicine ( ($EDIT) ) has issued an update. On May 26, 2026, Editas Medicine, Inc. suspended and...

2M ago

EDIT

Editas Medicine announces common stock, warrant offering, no amount given

Editas Medicine (EDIT) announced that it has commenced an underwritten public offering of its common stock and accompanying...

2M ago

EDIT

Editas Showcases Promising EDIT-401 Data for Hyperlipidemia

The latest update is out from Editas Medicine ( ($EDIT) ). On May 25, 2026, Editas Medicine presented...

2M ago

EDIT

Analyst Maintains Buy on Editas Medicine, Reiterates $5 Price Target on EDIT-401 Progress and Strong Cash Runway

H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on EDIT stock, giving a Buy rating on...

2M ago

EDIT

Editas Medicine presented preclinical data for EDIT-401 at EAS Congress

Editas Medicine (EDIT) presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an oral...

2M ago

EDIT

Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data

Editas Medicine ( ($EDIT) ) has issued an update. On May 14, 2026, at the American Society of...

2M ago

EDIT

Editas Medicine’s EDIT-401 shows efficacy and safety in hyperlipidemia

Editas Medicine (EDIT) shared new preclinical data supporting the continued advancement of Editas’ lead in vivo development candidate,...

2M ago

EDIT

FDA Commissioner Marty Makary resigns

Dr. Marty Makary, the commissioner of the Food and Drug Administration, resigned on Tuesday, according to multiple media...

2M ago

AZN

BMY

EDIT FAQ

What was Editas Medicine Inc’s price range in the past 12 months?

Editas Medicine Inc lowest stock price was $1.66 and its highest was $4.54 in the past 12 months.

What is Editas Medicine Inc’s market cap?

Editas Medicine Inc’s market cap is $457.32M.

When is Editas Medicine Inc’s upcoming earnings report date?

Editas Medicine Inc’s upcoming earnings report date is Aug 05, 2026 which is in 17 days.

How were Editas Medicine Inc’s earnings last quarter?

Editas Medicine Inc released its earnings results on May 05, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.263 by $0.003.

Is Editas Medicine Inc overvalued?

According to Wall Street analysts Editas Medicine Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Editas Medicine Inc pay dividends?

Editas Medicine Inc does not currently pay dividends.

What is Editas Medicine Inc’s EPS estimate?

Editas Medicine Inc’s EPS estimate is -0.27.

How many shares outstanding does Editas Medicine Inc have?

Editas Medicine Inc has 153,461,840 shares outstanding.

What happened to Editas Medicine Inc’s price movement after its last earnings report?

Editas Medicine Inc reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.263. Following the earnings report the stock price went up 1.333%.

Which hedge fund is a major shareholder of Editas Medicine Inc?

Currently, no hedge funds are holding shares in EDIT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Editas Medicine Stock Smart Score

Neutral

Fundamentals

Return on Equity

-677.38%

Trailing 12-Months

Asset Growth

-43.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine (EDIT) Earnings & Revenues

Historic Earnings Reports

EDIT Stock 12 Month Forecast

Average Price Target

$7.20

▲(106.30% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","4.75":"$4.75","8.5":"$8.5","12.25":"$12.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4.75,8.5,12.25,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.28,4.181538461538461,5.0830769230769235,5.984615384615385,6.886153846153846,7.787692307692307,8.68923076923077,9.590769230769231,10.492307692307692,11.393846153846154,12.295384615384615,13.196923076923078,14.098461538461539,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.28,3.5815384615384613,3.883076923076923,4.184615384615385,4.486153846153846,4.787692307692308,5.0892307692307694,5.390769230769231,5.6923076923076925,5.993846153846154,6.295384615384616,6.596923076923077,6.8984615384615395,{"y":7.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.28,3.335384615384615,3.3907692307692305,3.446153846153846,3.5015384615384613,3.5569230769230766,3.6123076923076924,3.667692307692308,3.723076923076923,3.7784615384615385,3.833846153846154,3.8892307692307693,3.9446153846153846,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >